<DOC>
	<DOCNO>NCT00522132</DOCNO>
	<brief_summary>The primary objective study evaluate effectiveness 2 intravenous artesunate dosing regimen ( 2.4 mg/kg initially 12 , 24 , 48 , 72 hour 4.0 mg/kg initially 24 48 hour ) clear P. falciparum parasites child severe malaria . Secondary objective include : - To compare tolerability safety 2 intravenous artesunate dosing regimen . - To evaluate difference pharmacokinetic profile intravenous artesunate patient age clinical presentation .</brief_summary>
	<brief_title>Phase II Artesunate Study Severe Malaria</brief_title>
	<detailed_description>This Phase II , double-blind , multicenter , randomize , parallel-group study antimalarial activity safety 2 intravenous artesunate regimen child severe P. falciparum malaria ( Appendix B ) . It compare efficacy , safety tolerability SEAQUAMAT regimen , recommend dose regimen adults,8 require twice daily artesunate dose first day , simpler daily regimen . The study also evaluate pharmacokinetic profile artesunate pediatric patient . Prior study initiation , protocol approve Independent Ethics Committee/Institutional Review Board ( ) ( IEC/IRB ) site national regulatory authority study site . Approximately 200 patient randomize 3 study site Africa , part Severe Malaria African Children ( SMAC ) network . Patients randomize 1 2 treatment cohort : - Cohort 1 : artesunate 2.4 mg/kg initially , 12 , 24 , 48 , 72 hour ( 12 mg/kg total dose ) ; - Cohort 2 : artesunate 4 mg/kg initially , 24 48 hour ( 12 mg/kg total dose ) , normal saline administer placebo 12 72 hour order maintain study blind . The study divide 3 main period include Pre-Treatment Period ( Screening/Day 0 ) , Treatment Period ( Days 0 3 ; Day 0 first day study drug dose ) , Post-Treatment Period ( include evaluation Days 7 , 14 , 28 ) . Children present study hospital signs/symptoms severe malaria screen study enrollment . Those presume severe malaria identify informed consent participation parents/guardians obtain confirmation malaria determine microscopic analysis Giemsa-stained thick smear . Patients meet study inclusion criterion none exclusion criterion randomize promptly treat 1 artesunate regimen , hospitalize least 4 day ( Days 0 , 1 , 2 , 3 ) . Adjunctive therapy , include fluid , glucose , blood , follow SMAC standard , base WHO guideline treatment severe malaria ( Appendix C ) . As soon patient able receive oral medication sign symptom severe malaria present , last pharmacokinetic sample take ( approximately 50 hour start therapy ) , single dose sulfadoxine/pyrimethamine administer ensure parasitological cure . Patients receive sulfadoxine/pyrimethamine within 14 day prior Study Day 0 receive mefloquine instead SP , , ensure effective parasitological cure . If parasitemia control safety laboratory test Day 3 indicate clinical concern warrant prolonged hospitalization , patient may discharge discretion investigator . If patient discharge hospital Day 3 , he/she return study site Day 7 evaluation . If patient unable tolerate oral liquid food within 6-24 hour last dose artesunate , patient continue hospitalize treated parenteral antimalarial therapy he/she able resume oral intake total 7 day therapy complete . All patient return study site evaluation Days 14 28 assess resolution clinical complication monitor safety therapy . Efficacy assess various parasite clearance parameter . Safety evaluation include physical examination , vital sign , hematology chemistry laboratory parameter monitor adverse event perform throughout study . Pharmacokinetic assessment perform 3 different timepoints study . If adverse event report study unresolved Day 28 , patient follow additional 30 day resolution event determination medical management deem necessary . Similarly , investigator instruct parents/guardians return patient study site untoward event occur within 30 day complete study drug .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Male female child age 6 month â‰¥ 5kg 10 year , inclusive . Clinical diagnosis severe P. falciparum malaria ( see Appendix B ) require hospitalization . Parasitemia ( 5,000 parasites/microL initial blood smear ) . Availability child 's parent/guardian willingness provide write informed consent accordance local practice . Willingness ability comply study protocol duration study . Willingness remain hospital 4 day Known serious adverse reaction hypersensitivity artemisinins , include artesunate , artemether , dihydroartemisinins CoArtem ( artemether/lumefantrine ) . Any underlying disease may compromise diagnosis evaluation response study medication ( include concomitant infection , concomitant neurological disease malnutrition ) Participation investigational drug study 30 day prior Screening . Adequate antimalarial treatment within 24 hour prior admission .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>intravenous artesunate</keyword>
	<keyword>severe malaria</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>Africa</keyword>
	<keyword>Severe Plasmodium falciparum Malaria</keyword>
</DOC>